Member Info for WeTookPelham

IMO...RE the 1 million trade, too much of a coincidence that it occurs on the morning of ASCO, no?

And we know it's purely a networking visit, and we know the CEO confirmed his attendance late in the day.

2+2=4 for a change?

Relatively speaking...today is not a normal day trading wise.

Maybe someone thinking ASCO isn't a jolly? 🤔

A buy? Not delayed either?

Absolutely spot on C11.

I was also trying to infer the significance of them not actually presenting, and the CEO fairly suddenly confirming his attendance as well

@violindog, "a jolly"? Seriously?

TF...good point RE it's ideal for ongoing discussions. Although I was more thinking they're not there to present something it seems.

Also...

"29/5/2025

14:31:49 rogerbridge: The previous Scancell announcement about one month ago stated Nermeen would attend the ASCO meeting. Phil, has now decided to attend.

Let’s hope he is meeting for some important discussions."

A frisson of excitement 🙂

Thanks BMG.

Somewhat short notice? And I assume they are there for networking purposes only going by that LinkedIn comment?

"...I've confirmed that many times before and every time you act surprised as if this was a revelation lmao."

No, the new, additional revelation is that you have no short term plan to invest either.

Lol...evil, no. But "everyone" on here has a reason/motive to post.

My point is you've confirmed now you've sold out and now you have said you have no immediate intention of buying. How do you think that come's across? I'll let everyone else interpret that for themselves.

But as mentioned, it could be absolute sheer boredom on your part. In which case, maybe crochet is something to look into?

I will say you do seem to have a good understanding of the science, which maybe you (try to) use to your advantage. And you do post some useful posts which I have recc'd belive it or not, but, purely IMO, there is underlying agenda here. Obviously I could be wrong there.

Anyway, onward & upwards.

@ST - are you posting/enquiring because you are thinking of buying back in? Genuine question.

Nice find CW.

The "C" word mentioned 3 x times no less...

"....This role is critical to ensuring that programs are efficiently delivered on schedule, and in alignment with corporate objectives, as well as regulatory and commercial requirements."

"...Collaborate with the Senior Leadership Team to shape strategic development plans, from discovery to commercialisation."

"...Strong understanding of the product development lifecycle, including preclinical research, clinical trial execution, product development, regulatory processes and commercial considerations."

P.s. #RentFree

Still posting about a stock your not invested in then ST? 🤣

What a way to use up one's precious time? Seriously.

As mentioned, either very lonely or just trying somewhat bizarrely to de-ramp?

Also...

"...As the most advanced hashtag#CancerVaccine of its kind, iSCIB1+ activates high-avidity T cells to generate a potent, lasting immune response with the potential to set a new benchmark in the treatment of advanced metastatic melanoma."

We saw that same wording on something else CW found, a presentation by Prof. Sarah ?

Anyway, either way it is very bullish wording IMO, especially coming from normally "hide behind the bushel" Scancell.

Very sad news.

Thanks for the update RW.

Highlights again why need companies, scientists and researchers like Scancell.

R.I.P. C7.

Ah, apologies CW.

Phil L'Huillier

Chief Executive Officer at Scancell Ltd

6 days ago

"Spent a thoroughly enjoyable and informative day at our SCOPE Clinical Study Investigator Meeting.

It was excellent to hear the enthusiasm for the Scancell DNA vaccine, SCIB1 and the 2nd product, iSCIB1+ from Heather Shaw and Pippa Corrie and all involved in the SCOPE study. Let me acknowledge the great work of Lindy Durrant, our CMO Nermeen Varawalla and the clinical team at the meeting and more importantly for the progress of the study as we embark on Cohort 4 with the Cancer Vaccine Launch Pad.

Thank you to all our investigators and nurses in centres around the country and also to the patients participating in the study."

For those on linkedin it's worth looking at the accompanying picture.

Purely IMO, everyone was caught off guard by the NHS partnership news which saw a near 40%(?) rise, extensive press and social media reporting, reports on national TV and an indirect mention by the UK prime minister no less. I don't think anyone really predicted this partnership news.

What this shows is that lots can and is going on in the background and we are none the wiser. I expect we will see similar out of the blue type news along with the data news.

I personally am very impressed by the new CEO Phil L'Hullier so far, he seems to be very focused and wants to deliver results. This IMO was sorely lacking previously.

"...In this video, our CEO Phillip L’ Huillier and CMO Dr. Nermeen Nermeen Varawalla discuss Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP), the next phase of our Phase 2 SCOPE study in advanced melanoma, and what this means for patients across the UK."

Not sure if this video was ever posted here? Apologies if so. But a nice easy to understand explanation of the partnership.

https://www.linkedin.com/posts/scancell-limited_cancerresearch-immunooncology-biotech-activity-7317531907263455233-TFjR

"...Individuals with expertise in GMP and a track record of leading CMC activities to support product registrations and commercialisation are strongly encouraged to apply."

Make of that what you will.